Patents by Inventor Sui Xiong Cai

Sui Xiong Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7015328
    Abstract: The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I: wherein A, B, X, Y, and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: March 21, 2006
    Assignees: Cytovia, Inc., Shire BioChem Inc.
    Inventors: Sui Xiong Cai, Hong Zhang, William E. Kemnitzer, Songchun Jiang, John Drewe, Richard Storer
  • Patent number: 6984718
    Abstract: The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: January 10, 2006
    Assignee: Cytovia, Inc.
    Inventors: Han-Zhong Zhang, Sui Xiong Cai, John A. Drewe, Wu Yang
  • Patent number: 6949516
    Abstract: The present invention is directed to novel dipeptides thereof, represented by the general Formula I: where R1-R3 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: September 27, 2005
    Assignee: Cytovia, Inc.
    Inventors: John F. W. Keana, Sui Xiong Cai, John Guastella, Wu Yang, John A. Drewe, Eckard Weber
  • Patent number: 6906203
    Abstract: The present invention is directed to substituted 4H-chromene and analogs thereof, represented by the general Formula I: wherein A, B, X, Y, Z and R5 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: June 14, 2005
    Assignee: Cytovia, Inc.
    Inventors: John A. Drewe, Sui Xiong Cai, Yan Wang
  • Patent number: 6900325
    Abstract: The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I: wherein A, B, X, Y, and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: May 31, 2005
    Assignees: Cytovia, Inc., Shire BioChem Inc.
    Inventors: Sui Xiong Cai, Hong Zhang, William E. Kemnitzer, Songchun Jiang, John Drewe, Richard Storer
  • Patent number: 6861419
    Abstract: The present invention is directed to substituted 1,4-thiazepine and analogs thereof, represented by the general Formula I: wherein the dashed lines, A1, A2, A3, X1 and R1 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of capases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: March 1, 2005
    Assignee: Cytovia, Inc.
    Inventors: John A. Drewe, Sui Xiong Cai, Emma Jane Shelton, Joane Litvak, David Sperandio, Jeffrey R. Spencer, Martin Sendzik
  • Patent number: 6858607
    Abstract: The present invention is directed to substituted 4H-chromene and analogs thereof, represented by the general Formula I: or pharmaceutically acceptable salts or prodrugs thereof, wherein: wherein A, R1, R2, R5, X, Y, and Z, are defined herein and B is a fused thiazole, oxazole, 2-imino-imidazole, 2,1,3-thiadiazo-2-one, thiazol-2-one, oxazol-2-one, imidazol-2-thione, thiazol-2-thione, oxazol-2-thione, imidazoline, oxazoline, thiazoline, triazole, oxazine, oxazine-2,3-dione, or piperazine ring. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: February 22, 2005
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Lifen Xu, Richard Storer, Giorgio Attardo
  • Publication number: 20040235846
    Abstract: The present invention is directed to substituted nicotinamides and analogs thereof, represented by Formula V: 1
    Type: Application
    Filed: June 28, 2004
    Publication date: November 25, 2004
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe
  • Patent number: 6800657
    Abstract: Disclosed is a method for treating a disorder responsive to the positive modulation of AMPA receptors in animals suffering therefrom, comprising administering to an animal in need thereof a compound of Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is NH2, NHR, and NHCOR; Z is O and S; and R1, R2, R3, R4, and X are defined herein. These compounds can be used as cognitive enhancers, for the treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, AIDS associated dementia and Down's syndrome as well as for the treatment of schizophrenia and myoclonus. Also disclosed are pharmaceutical compositions useful for treating disorders responsive to the positive modulation of AMPA receptors, and novel compounds of Formula I.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: October 5, 2004
    Assignee: Euro-Celtique S.A.
    Inventors: Christopher S. Konkoy, David B. Fick, Sui Xiong Cai, Nancy C. Lan, John F. W. Keana
  • Publication number: 20040191844
    Abstract: The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.
    Type: Application
    Filed: April 22, 2004
    Publication date: September 30, 2004
    Applicant: Cytovia, Inc.
    Inventors: Eckard Weber, Sui Xiong Cai, John F.W. Keana, John A. Drewe, Han-Zhong Zhang
  • Publication number: 20040186078
    Abstract: The present invention is directed to substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: 1
    Type: Application
    Filed: April 5, 2004
    Publication date: September 23, 2004
    Inventors: Sui Xiong Cai, Shailaja Kasibhatla, John Drewe, P. Sanjeeva Reddy, Han-Zhong Zhang
  • Patent number: 6794397
    Abstract: The present invention is directed to substituted nicotinamides and analogs thereof, represented by Formula V: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Ar′ and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and R11 is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted. The present invention also relates to the discovery that compounds having Formula V are activators of caspases and inducers of apoptosis. Therefore, the compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: September 21, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe
  • Patent number: 6794400
    Abstract: The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: wherein A1, A2, Q and R1-R3 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: September 21, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Bao Ngoc Nguyen, John Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Azra Pervin
  • Publication number: 20040171637
    Abstract: The present invention is directed to multifluoro-substituted Chalcones and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: October 16, 2003
    Publication date: September 2, 2004
    Inventors: Sui Xiong Cai, P. Sanjeeva Reddy, John A. Drewe, Bao Ngoc Nguyen, Shailaja Kasibhatla
  • Patent number: 6759207
    Abstract: The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: July 6, 2004
    Assignee: Cytovia, Inc.
    Inventors: Eckard Weber, Sui Xiong Cai, John F. W. Keana, John A. Drewe, Han-Zhong Zhang
  • Publication number: 20040127521
    Abstract: Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: 1
    Type: Application
    Filed: December 18, 2003
    Publication date: July 1, 2004
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, Jared D. Kuemmerle, Hong Zhang, William E. Kemnitzer
  • Publication number: 20040116355
    Abstract: The present invention is directed to novel dipeptide thereof, represented by the general Formula I: 1
    Type: Application
    Filed: November 26, 2003
    Publication date: June 17, 2004
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Eckard Weber, Yan Wang, Gordon B. Mills, Douglas R. Green
  • Patent number: 6747052
    Abstract: The present invention is directed to substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs thereof, represented by the general Formula I: wherein X, Ar1, R2-R6 and R12 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: June 8, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Han-Zhong Zhang
  • Publication number: 20040097581
    Abstract: Disclosed is a method for treating a disorder responsive to the positive modulation of AMPA receptors in animals suffering therefrom, comprising administering to an animal in need thereof a compound of Formula I: 1
    Type: Application
    Filed: July 2, 2003
    Publication date: May 20, 2004
    Inventors: Christopher S. Konkoy, David B. Fick, Sui Xiong Cai, Nancy C. Lan, John F.W. Keana
  • Publication number: 20040097503
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: November 10, 2003
    Publication date: May 20, 2004
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, P. Sanjeeva Reddy, Bao Nguyen, Azra Pervin